ANTIVIRAL DRUGS ADVISORY COMMITTEE

October 4, 2001

NDA 21-266, Vfend (voriconazole) Tablets and NDA 21-267, Vfend I.V. (voriconazole) for infusion, Pfizer Global Research and Development.
Proposed for the treatment of invasive aspergillosis, serious Candida infections, infections caused by Scedosporium spp. and Fusarium spp., rar and refractory infections and empirical treatment of febril neutropenia.

Briefing Information

Pfizer Global Research and Development

Disclaimer

The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Document pdf

FDA Briefing Information

Briefing Document   pdf    htm

Errata   pdf   htm  (new 10/04/01)